Janssen gets diabetes CRL

Share this article:

The FDA issued a Complete Response Letter to Janssen, telling the drugmaker it needs more data about the experimental canagliflozin-metformin treatment for diabetes. The Johnson & Johnson subsidiary said in a statement that the FDA wants data indicating that canagliflozin—known by the brand Invokana, approved earlier this year—is as effective in the combined form as it is when used as a standalone treatment.

PMLive notes that the CRL is not much of a setback for Janssen, because doctors can prescribe the two drugs separately if they want to use them in tandem. The site also notes that the combination is not a unique one—Bristol-Myers Squibb and AstraZeneca are already marketing a dapagliflozin-metformin mix abroad under the brand Xigduo.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.